Pharmaceutical intelligence for Tarix Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Assets: 1

Recent signals(1)

ClinicalJuly 19, 2026

Study on 124I-cG250 PET/CT for Early Detection of Therapy Response in Metastatic Renal Cell Carcinoma

A study is evaluating the effectiveness of 124I-cG250 PET/CT scans in detecting early responses to sunitinib or pazopanib in kidney cancer patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJuly 19, 2026

Study on 124I-cG250 PET/CT for Early Detection of Therapy Response in Metastatic Renal Cell Carcinoma

A study is evaluating the effectiveness of 124I-cG250 PET/CT scans in detecting early responses to sunitinib or pazopanib in kidney cancer patients.

Competitive activity

No signals indexed for this entity yet.

Assets

sunitinib →

Therapeutic areas

Oncology →

Oncology · Renal Cell Carcinoma →

Renal Cell Carcinoma →

Indications

Renal Cell Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.